Clinical trial · Observational
The Delayed Intervention and Surveillance for Small Renal Masses (DISSRM) Registry
NCT02346435CI-TRIAL-00104687DISSRMrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Retrospective studies indicate that active surveillance for clinically localized, small renal masses (cT1a, \<=4cm) is safe. It is our hypothesis that active surveillance is safe and efficacious when compared prospectively to patients undergoing immediate intervention for their small renal mass.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Kidney Neoplasm | Kidney Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (3)
- label
- Active Surveillance
- label
- Immediate Intervention
- description
- May include patients undergoing open or minimally-invasive partial nephrectomy, radical nephrectomy or energy ablation.
- label
- Crossover (Delayed Intervention)
- description
- Initially patients in active surveillance that meet progression criteria or elect to undergo delayed intervention.
Primary outcomes (1)
- measure
- Disease-specific survival
- timeFrame
- 5 years
- description
- Safety and Efficacy of active surveillance and delayed intervention for the SRM, measured by disease-free survival at 5-years.
Secondary outcomes (3)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 100 Years
Show eligibility criteria text
Inclusion Criteria: * Must have a solid, enhancing renal mass ≤4cm at its greatest dimension found on incidental scanning in the last 6 months. * Age ≥ 18 and able to read, understand and sign informed consent. * Must be willing to adhere to the treatment algorithm and time constraints therein. Exclusion Criteria: * Cannot have suspicion of metastases to the kidney if any other malignancy diagnosed within two years of study entry.
References
Publications (1)
- DERIVEDAlkhatib KY, Cheaib JG, Pallauf M, Alam R, Patel HD, Wlajnitz T, Singla N, Chang P, Wagner AA, Pavlovich CP, McKiernan JM, Guzzo TJ, Allaf ME, Pierorazio PM. Active Surveillance vs Primary Intervention for Clinical T1a Kidney Tumors: 12-Year Experience of the Delayed Intervention and Surveillance for Small Renal Masses Prospective Comparative Study. J Urol. 2025 Aug;214(2):197-209. doi: 10.1097/JU.0000000000004583. Epub 2025 Apr 22. PMID 40262276